Baxter International Inc (NYSE:BAX) gets upgraded to Overweight by Morgan Stanley

Analyst Ratings For Baxter International Inc (NYSE:BAX)

Story continues below

Today, Baxter International Inc (NYSE:BAX) stock received an upgrade by Morgan Stanley from Equal Weight to Overweight.

There are 14 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on Baxter International Inc (NYSE:BAX) is Buy with a consensus target price of $74.7647 per share, a potential 13.59% upside.

Some recent analyst ratings include

  • 1/2/2019-Baxter International Inc (NYSE:BAX) gets upgraded to Overweight by Morgan Stanley
  • 1/2/2019-Baxter International Inc (NYSE:BAX) gets upgraded to Buy by Citigroup
  • 12/17/2018-Baxter International Inc (NYSE:BAX) has coverage initiated with a Outperform rating and $77.00 price target
  • 11/27/2018-Baxter International Inc (NYSE:BAX) has coverage initiated with a Buy rating and $80.00 price target
  • 11/2/2018-Baxter International Inc (NYSE:BAX) gets upgraded to Buy by Argus with a price target of $70.00
  • On 12/13/2018 John D Forsyth, Director, sold 1,500 with an average share price of $67.02 per share and the total transaction amounting to $100,530.00.
  • On 12/3/2018 Carole J Shapazian, Director, sold 11,749 with an average share price of $68.48 per share and the total transaction amounting to $804,571.52.
  • On 12/3/2018 Third Point Llc, Insider, sold 8,000,000 with an average share price of $68.62 per share and the total transaction amounting to $548,960,000.00.
  • On 9/17/2018 Giuseppe Accogli, SVP, sold 17,647 with an average share price of $77.27 per share and the total transaction amounting to $1,363,583.69.
  • On 8/8/2018 Carole J Shapazian, Director, sold 5,400 with an average share price of $72.97 per share and the total transaction amounting to $394,038.00.
  • On 7/10/2018 Scott Pleau, SVP, sold 10,686 with an average share price of $75.00 per share and the total transaction amounting to $801,450.00.
  • On 6/25/2018 Scott Pleau, SVP, sold 27,197 with an average share price of $73.57 per share and the total transaction amounting to $2,000,883.29.

About Baxter International Inc (NYSE:BAX)
Baxter International Inc. provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies. The company also provides biological products and medical devices, and surgical hemostat and sealant products used in surgical procedures for hemostasis, tissue sealing, and adhesion prevention; premixed and oncology drug platforms, inhaled anesthesia and critical care products, and pharmacy compounding services; and generic injectable pharmaceuticals. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and by patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was founded in 1931 and is headquartered in Deerfield, Illinois.

Recent Trading Activity for Baxter International Inc (NYSE:BAX)
Shares of Baxter International Inc closed the previous trading session at 65,82 +0,61 0,94 % with 66.23 shares trading hands.

An ad to help with our costs